---
title: "Serina Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286460398.md"
datetime: "2026-05-14T20:10:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286460398.md)
  - [en](https://longbridge.com/en/news/286460398.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286460398.md)
---

# Serina Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.58, missing the estimate of USD -0.44.

EBIT: As of FY2026 Q1, the actual value is USD -6.091 M.

#### Operational Metrics

Operating expenses for the three months ended March 31, 2026, were $6.3 million, compared to $5.9 million for the same period in 2025.

#### Research and Development (R&D) Expenses

R&D expenses were $3.2 million for the three months ended March 31, 2026, an increase from $3.0 million for the same period in 2025.

#### General and Administrative Expenses

General and administrative expenses increased to $3.1 million for the three months ended March 31, 2026, from $2.9 million in the prior year period.

#### Other Expense, Net

Other expense, net was -$0.6 million for the three months ended March 31, 2026, a change from $1.0 million other income for the same period in 2025. This -$1.6 million increase in expenses was primarily due to a non-cash loss on extinguishment of financial commitment assets and contingent warrants related to the amendment of the Senior Unsecured Convertible Promissory Note.

#### Net Loss

The net loss attributable to Serina Therapeutics, Inc. for the three months ended March 31, 2026, was -$6.9 million, compared to a net loss of -$4.8 million for the same period in 2025.

#### Cash and Cash Equivalents

Cash and cash equivalents totaled $24.5 million as of March 31, 2026, significantly up from $3.056 million as of December 31, 2025. Additionally, gross proceeds of $5.2 million were received in April 2026 from the March 2026 private placement financing.

#### Cash Flow from Operating Activities

Net cash used in operating activities was -$4.568 million for the three months ended March 31, 2026, compared to -$4.322 million for the same period in 2025.

#### Cash Flow from Investing Activities

Net cash used in investing activities was -$0.025 million for the three months ended March 31, 2026, with no cash used in investing activities for the same period in 2025.

#### Cash Flow from Financing Activities

Net cash provided by financing activities was $26.057 million for the three months ended March 31, 2026, an increase from $4.917 million for the same period in 2025.

#### Balance Sheet Highlights

As of March 31, 2026, total assets were $27.299 million, total liabilities were $9.671 million, and total stockholders’ equity was $17.628 million.

#### Key Financial Events

Serina Therapeutics, Inc. closed a private placement financing in March and April 2026, resulting in aggregate gross proceeds of $21.2 million. This financing led to the amendment of a Senior Unsecured Convertible Promissory Note and the automatic conversion of Series A Preferred Stock into common stock.

#### Outlook

Serina Therapeutics, Inc. anticipates completing enrollment and dosing of Cohort 1 for its SER-252 Phase 1b registrational clinical study by the end of the third quarter of 2026. The company is targeting the availability of TFL data from the SAD study arm in the first half of 2027.

### Related Stocks

- [SER.US](https://longbridge.com/en/quote/SER.US.md)

## Related News & Research

- [Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | SER Stock News](https://longbridge.com/en/news/286462168.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [REEVES CONFIRMS NO INCREASE IN UK FUEL DUTY IN 2026](https://longbridge.com/en/news/287213292.md)